Beneficial Ownership Report · SCHEDULE 13G/A
Immunic, Inc.
IMUXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Immunic, Inc.
- Company CIK
- 0001280776
- Street
- 1200 Avenue of the Americas
- Street (continued)
- Suite 200
- City
- New York
- State / country code
- NY
- Postal code
- 10036
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- OrbiMed Advisors LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Aggregate amount owned
- 314,409.00
- Percent of class
- 2.3
- Sole voting power
- 0.00
- Shared voting power
- 314,409.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 314,409.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- OrbiMed Genesis GP LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Aggregate amount owned
- 314,409.00
- Percent of class
- 2.3
- Sole voting power
- 0.00
- Shared voting power
- 314,409.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 314,409.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- OrbiMed Capital LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Aggregate amount owned
- 161,395.00
- Percent of class
- 1.2
- Sole voting power
- 161,395.00
- Shared voting power
- 0.00
- Sole dispositive power
- 161,395.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Immunic, Inc.
Principal executive office address
1200 Avenue of the Americas, Suite 200, New York, NY 10036
Item 2
Citizenship
Please refer to Item 4 on each cover sheet for each filing person.
Filing person
OrbiMed Advisors LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC
Principal business or residence address
601 Lexington Avenue, 54th Floor, New York, NY 10022
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
OrbiMed Advisors LLC: 2.3% OrbiMed Genesis GP LLC: 2.3% OrbiMed Capital LLC: 1.2%
Amount beneficially owned
OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 161,395
Sole voting power
OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0 OrbiMed Capital LLC: 161,395
Shared voting power
OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 0
Sole dispositive power
OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0 OrbiMed Capital LLC: 161,395
Shared dispositive power
OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 0
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
The Reporting Persons hold 3.5% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- OrbiMed Advisors LLC
- Signed
- /s/ Carl L. Gordon
- Title
- Carl L. Gordon / Member
- Date
- 11/16/2026
Signature 2
- Reporting person
- OrbiMed Genesis GP LLC
- Signed
- /s/ Carl L. Gordon
- Title
- Carl L. Gordon / Member
- Date
- 11/16/2026
Signature 3
- Reporting person
- OrbiMed Capital LLC
- Signed
- /s/ Carl L. Gordon
- Title
- Carl L. Gordon / Member
- Date
- 11/16/2026
Filed exhibits
- JOINT FILING AGREEMENT ↗ss7058510_ex99a.htm
Company context
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.